Clinical Efficacy of Targeted Biologic Agents as Second‐Line Therapy of Advanced Thyroid Cancer

Learning Objectives List the therapeutic opportunities with tyrosine kinase inhibitors for advanced thyroid cancer, especially in the frontline setting. Describe and discuss the current knowledge and experience with salvage therapy with biologic agents for thyroid cancer. Introduction. Targeted biol...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2013-12, Vol.18 (12), p.1262-1269
Main Authors: Owonikoko, Taofeek K., Chowdry, Rajasree P., Chen, Zhengjia, Kim, Sungjin, Saba, Nabil F., Shin, Dong M., Khuri, Fadlo R.
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biologic agents
Carcinoma, Neuroendocrine
Disease-Free Survival
Endocrinology
Everolimus
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Molecular Targeted Therapy - methods
Niacinamide - administration & dosage
Niacinamide - analogs & derivatives
Niacinamide - therapeutic use
Phenylurea Compounds - administration & dosage
Phenylurea Compounds - therapeutic use
Piperidines - administration & dosage
Piperidines - therapeutic use
Quinazolines - administration & dosage
Quinazolines - therapeutic use
Retrospective Studies
Second‐line
Sirolimus - administration & dosage
Sirolimus - analogs & derivatives
Sirolimus - therapeutic use
Sorafenib
Thyroid cancer
Thyroid Neoplasms - chemically induced
Thyroid Neoplasms - drug therapy
Thyroid Neoplasms - mortality
Thyroid Neoplasms - pathology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Learning Objectives List the therapeutic opportunities with tyrosine kinase inhibitors for advanced thyroid cancer, especially in the frontline setting. Describe and discuss the current knowledge and experience with salvage therapy with biologic agents for thyroid cancer. Introduction. Targeted biologic agents showed clinically meaningful efficacy as front‐line therapy for advanced radioiodine‐refractory and medullary thyroid cancer. The clinical benefit of these agents beyond the front line has yet to be established. Methods. We assessed the clinical benefit of targeted agents in patients with advanced differentiated and medullary thyroid cancer treated at a single academic cancer center. We determined efficacy and compared front‐line and second‐line benefit using biochemical and anatomic response, time to treatment failure, and progression‐free survival (PFS). Statistical differences were assessed by t test and chi‐square test. Survival curves were generated by the Kaplan‐Meier method. Differences in survival were assessed using the log‐rank test, and a p value
ISSN:1083-7159
1549-490X
DOI:10.1634/theoncologist.2013-0250